The agreement grants Pediapharm exclusivity in the territory for the distribution and marketing of EpiCeram while Ceragenix will be responsible for the manufacturing and supply of the product. Pediapharm is also responsible for obtaining regulatory clearance to market EpiCeram in the territory. Financial terms were not disclosed.
Steven Porter, chairman and CEO of Ceragenix said, We are delighted to enter the Canadian market with Pediapharm. We believe that their focus on the pediatric market is a very good strategic fit for EpiCeram.
Ceragenix Pharmaceuticals is a biopharmaceutical and medical device company engaged in the discovery, development, and commercialization of a portfolio of innovative products in the fields of infectious disease and dermatology.
Pediapharm is a pediatric specialty pharmaceutical company, which provides sales and marketing expertise for the pediatric market segment. Through its network pediatricians and pharmacies, Pediapharm’s key objectives are to partner with healthcare entities around the world and bring NEW innovative or existing OTC and Rx pediatric products to the Canadian market.